Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice
© Eppeland et al.; licensee BioMed Central Ltd. 2013
Received: 5 October 2012
Accepted: 30 April 2013
Published: 7 May 2013
From a health service perspective, society, with its limited resources, needs to be reassured that evidence-based medicine is also effective when carried out in the frame of ordinary clinical practice. The effectiveness of rehabilitation programs in ankylosing spondylitis (AS) has been proven to be effective in clinical trials. However, less is known when this is carried out in clinical practice. The aim of this study was to evaluate the effect of a 2-weeks rehabilitation program on self-reported outcome and physical function in patients with axial spondyloarthritis (ax-SpA) including AS patients carried out in ordinary clinical practice. The program contained of daily water exercises, exercises for flexibility, muscle strength, and cardio-respiratory fitness.
A total of 87 ax-SpA patients (60 men, 27 women), aged ≥ 18 years were identified to have participated in the 2-weeks in-patient rehabilitation program. Mean age was 49 years and disease duration was 14 years. 92.5% were HLA-B27 positive, 62% were current users of non-steroidal anti-inflammatory drugs, and 17% were current users of tumour necrosis factor inhibitors. After 2-weeks, a statistical significant improvement (p < 0.001) was observed for patient-reported outcomes (Bath Ankylosing Spondylitis (BAS) Disease Activity Index 4.3 vs. 3.1, BAS Functional Index 3.1 vs. 2.4) and physical measured outcomes (BAS Metrology Index 3.23 vs. 2.29, Gait Velocity 2.2 vs. 2.6 m/s, timed-stands test 22.5 vs. 16.3 s, finger-floor distance 17.9 vs. 8.9 cm, chest expansion 3.9 vs. 4.6 cm).
Data, from our retrospective case series report, support that patient with ax-SpA benefit from short-term rehabilitation when it is carried out in ordinary clinical care. Data from ordinary clinical care may be important when discussing the effectiveness of a treatment and allocating resources in the health care system.
Axial Spondyloarthritis (ax-SpA) is diagnosed when signs and symptoms caused by chronic inflammation in the axial skeleton is present. Inflammation in the axial skeleton causes pain, stiffness and limitation of thoracic and spinal mobility. The imaging hallmark of ax-SpA is sacroiliitis visible, e.g. on radiographs or magnetic resonance imaging (MRI) and signs of new bone formations in the axial skeleton . Ankylosing spondylitis (AS) is a phenotype of ax-SpA, diagnosed by the presence of sacroiliitis on radiographs, which in its final stage may cause ankylosing at sacroiliac joints and the spine . Apart from pharmacological treatment (Non Steroidal Anti-Inflammatory Drugs (NSAIDs) and anti-Tumour Necrosis Factor (TNF) -α treatment), exercise and rehabilitation therapy are cornerstones in the management of ax-SpA including AS [3, 4].
There is a substantial body of evidence in the literature proving that various spa and exercise programs tested in randomised trials have a beneficial effect in AS patients improving physical function and reducing symptoms of disease [5–12]. In a recent review, the authors concluded that physical therapy exercises in various modalities have positive effects on BASFI, BASDAI, pain and mobility outcomes . Furthermore, in a Cochrane review, the results suggested individual home-based or supervised exercise programs to be better than non-intervention, supervised group physiotherapy to be better than home-exercise, and combined in-patient spa-exercise therapy followed by group physiotherapy to be better than group physiotherapy alone . This knowledge is reflected in recommendations for management of AS, highlighting that regular exercise and rehabilitation therapy are part of the treatment strategy [3, 15].
The gold standard for treatment in modern medicine is based on evidence from randomised clinical trials. However, the knowledge on the benefit and effect of a treatment and/or an intervention carried out in daily clinical care is also important and essential for patients, health care providers and decision makers in the health care system [16, 17]. This can reassure that treatment based on evidence is also effective when applied in daily clinical practice.
The main aim of this study was to evaluate the short-term effect of an in-patient 2-weeks rehabilitation and exercise program on self-reported outcome and physical functions in ax-SpA patients, within the frame of standard routine and clinical care.
In this retrospective case series report we retrieved from our hospital database ax-SpA patients who had participated in our 2-weeks in-patient rehabilitation intervention program in the period from January 2007 to June 2011. The Department of Rheumatology is the only one of its kind located in the geographic area of southern Norway with a population of approximately 200 000 inhabitants, aged 20 years and older. All included patients had to be ≥18 years of age and have a diagnosis of ax-SpA with imaging findings on X-ray, computer tomography (CT) and/or MRI confirming sacroiliitis.
Patient-reported outcome measures (PROMs), therapist measured outcomes and laboratory data in axial spondyloarthritis patients following a 2-weeks in-patient rehabilitation and training program
BASDAI, 0–10 scale
BASFI, 0–10 scale
Therapist measured outcomes
BASMI, 0–10 scale
Gait velocity, m/s
Timed-stand test, s
Finger-to-floor distance, cm
Chest expansion, cm
The multidisciplinary team at the rehabilitation unit consists of rheumatologist, physiotherapist, occupational therapist, social worker, and secretary. The training program, which was performed 5 days a week, was organised by an experienced physiotherapist and based on current evidence-based knowledge. The daily rehabilitation program consists of water exercises (30 minutes), basic exercises for movement, muscle strength and stability, balance and coordination (45 minutes), and exercises for endurance (40 minutes), aiming at keeping the training intensity as recommended in the literature . The training is instructed by a physiotherapist in groups of four, but with an individual focus according to the individual goals and statuses of the patients. In addition, every patient has daily individual physiotherapy including massage, stretching, mobilisation/articulation and advice on specific exercises to enhance a good body posture. The patients were also followed up as needed by the other professions listed above.
We also aimed to collect data on BASDAI, BASFI and BASMI from the first follow-up at the outpatient clinic after the training program. These data were collected as part of a clinical visit at the rheumatology out-patient clinic were retrieved from the hospital database.
We used the SPSS statistical program, version 16.0 to do the statistical analysis. Normal distributed data were presented as mean with standard deviation (SD) and data with skewed distribution were also presented as median with inter-quartile range (25th–75th percentiles).
For group comparison, we used paired Student’s t-test for continuous variables. If continuous variables had a skewed distribution, we also performed a non-parametric Wilcoxon test. For variables with a statistically significant difference between baseline and 2 weeks follow-up, the change from baseline to 2 weeks was also presented as a percentage change with 95% confidence intervals (CI). The physiotherapist involved in patient assessment (SGE) did not analyse the data.
The study was approved by the regional committee for ethics and medical research (REK sør-øst, Norway).
For the assessment period 95 ax-SpA patients started the 2-week rehabilitation program. Among them 8 patients (6 men and 2 women) did not complete the 2-week program for various reasons including acute infectious diseases, acute low back pain, depression and vertigo. A total of 87 ax-SpA patients were thus eligible for evaluation (60 men and 27 women). Mean (SD) age was 49.2 (10.0) years, body mass index (BMI) was 26.7 kg/m2 (3.5), education was 12.2 (4.0) years, and disease duration was 14.4 years (11.9). Among the patients, 92.5% were HLA-B27 positive and 27.2% were smoking. Furthermore, 50.6% were employed, 9.2% had combined disability pension and were employed part-time and 29.9% had a disability pension. Among the patients, 62.1% were current users of NSAIDs and 17.2% of TNF inhibitors (10 etanercept, 3 infliximab and 2 adalimumab). All patients fulfilled the Assessment of SpondyloArthritis international Society (ASAS) criteria for axial spondyloarthritis . All patients had imaging evidence of sacroiliitis. Among the 72 patients with available radiographs of the sacroiliac joint 64 patients had radiographic sacroiliitis and fulfilled the modified New York criteria for AS . Among the 23 patients not fulfilling the New York criteria for AS, 18 patients had sacroiliitis on MRI and 5 patients had sacroiliitis on CT.
As shown in Table 1, a statistical significant improvement (p < 0.001) was observed both for patient-reported and physical-measured outcomes after 2 weeks. Expressed as percentages (95% CI), the improvement for mean BASDAI was 27% (18–37%), for BASFI 26% (15–37%), for BASMI 29% (22–36%), for gait velocity 20% (17–23%), for timed-stand test 27% (23–32%), for finger-to-floor distance 40% (26–53%) and chest expansion 26% (19–33%). However, no significant differences were seen for ESR (16.5 vs. 16.9 mm/hr) and CRP (8.2 vs. 8.3 mg/l).
Among the 48 ax-SpA patients with retrievable follow-up data, no significant differences were seen in a mean time-period of 9.3 months (SD 6.9) after the training program for BASDAI [mean 4.4 (2.2) vs 4.1 (2.3), p = 0.24] and BASFI [mean 3.5 (2.6) vs 3.2 (2.0), p = 0.31]. However, BASMI at follow-up remained significantly improved, compared with the baseline [mean 2.7 (2.5) vs 3.3 (2.6), p = 0.02].
Our study supports that patients with ax-SpA, benefit from structured and intensive exercise training programs, and also when these are carried out in the setting of ordinary clinical practice. In our study, ax-SpA patients improved self-reported disease activity by 27% (BASDAI) and function by 26% (BASFI), whereas improvement in physical measured function ranged from 20% for gait velocity to 40% for finger-to-floor distance.
Various exercise and rehabilitation programs proving efficacy have been tested in randomised trials [5–12]. This includes different exercise programs [9, 10, 12], spa rehabilitation and exercise programs [6, 7], combined intensive group exercise with an educational-behavioural program , and rehabilitation and exercise programs tested in different climates . In a Cochrane review of the literature, it was concluded that supervised group therapy was better than home exercises, and combined in-patient spa-exercise therapy followed by group physiotherapy was better than group physiotherapy alone . In our study, exercises were carried out in groups.
In the study by Strumse et al., comparing a 4-weeks rehabilitation program in Mediterranean and Norwegian settings , patients in the Norwegian environment reduced their BASDAI by 1.9 from a baseline of 5.8 (33%) and BASFI by 1.2 from a baseline of 4.3 (28%) which is in the same percentage range as in our study. Patients, however, in the Mediterranean setting had a significantly higher reduction than for patients in the Norwegian setting with a reduction in BASDAI by 4.2 from a baseline of 6.2 (68%) and BASFI by 2.6 from a baseline of 4.3 (60%). The results of this study indicate that warm climate does have an additional effect on rehabilitation and exercise programs for the AS patients. The baseline values in this study were, however, higher than in our study.
Pharmacological treatment with NSAIDs  and TNF inhibitors [24–26] has proven to improve signs and symptoms and to improve physical function in AS. NSAIDs are considered as first-line in pharmacological treatment of AS, whereas, TNF inhibitors are recommended used in patients with active disease when exercise, and physiotherapy and NSAIDs have failed . In our study, 62% were NSAID and 17% were current users of TNF inhibitors. In the ASSERT-infliximab study, evaluating the efficacy of infliximab in AS patients with active disease at inclusion (BASDAI ≥ 4), patients improved in median their BASDAI by 2.9, BASFI by 1.7 and BASMI by 1.0 scale points during 24 weeks of follow up, reflecting a percentage improvement by, approximately, 45% for BASDAI, 30% for BASFI and 21% for BASMI . The same level of improvement rates has also been reported for other TNF inhibitors, e.g. adalimumab and etanercept [25, 26]. Interestingly, the corresponding figures for percentage changes for BASDAI, BASFI and BASMI in our study were in the same range as for these studies exploring the effect of TNF inhibition. This emphasises and illustrates the effectiveness of exercise programs in AS patients.
In the randomised, controlled study by Masiero et al., was demonstrated that even AS patients stabilised on TNF inhibitors were able to further improve spine mobility and reduce pain, stiffness, and disability by a rehabilitation program based on an educational-behavioral intervention and exercise training program . In the study by Colina et al., an intensive rehabilitation program in AS patients treated with the TNF-inhibitor etanercept was shown to contribute to reducing disability and to ameliorating quality of life . These points highlight that exercise programs should be part of the treatment strategy, even in patients who have responded favourably to anti-TNF treatment. The importance of exercise programs in AS is further highlighted by evidence suggesting that AS patients are at increased risk of cardiovascular diseases . In a recently published cross-sectional study, AS patients were found not only to have reduced flexibility, but also to have lower cardio-respiratory fitness, again underlining the importance of exercising in this patient group .
Exercise programs have also been proven to be cost effective. A randomised controlled trial showed that combined spa-exercise therapy with drugs and weekly group physical therapy had a more favourable cost-effectiveness and cost-utility compared with patients who stayed at home and continued their usual activities and standard treatment .
One of the big challenges is patient’s adherence to the exercise program . In a recent publication, evaluating exercise programs, it was found that only four trials reported on participants’ adherence to the exercise programs and that only one provided sufficient information to evaluate the possible influence of the adherence . Our data indicate that the positive effects on self-reported disease activity (BASDAI) and function (BASFI) gained from the training program are lost and diminished after the training program is stopped. In a recently published prospective Norwegian study, it was found that patients were back to their base-line health status six months after discharge from rehabilitation . This highlights the importance of supporting patients and encouraging them to continue exercising and also, after finishing intensive exercise programs, to maintain the levels of benefits that have been achieved.
One of the major challenges comparing the results between rehabilitation studies is the lack of standardisation and the variation in the content, exercise intensity and duration. In our study, the intervention period was 5 days a week for 2 weeks, whereas, e.g. in the study by Colina et al.,  the intervention period was one week and in the study by Ince et al., the period was three months . In our study, the daily program consisted of water exercises (30 minutes), basic exercises for movement, muscle strength and stability, balance and coordination (45 minutes), and exercises for endurance (40 minutes). In addition, every patient had daily individual physiotherapy including massage, stretching, mobilisation and articulation, and advice on specific exercises to enhance a good body posture. In the study by Ince et al., the exercise program consisted of 50 minutes of multimodal exercise, including aerobic, stretching, and pulmonary exercises, 3 times a week for 3 months . Whereas, in the study by Masiero et al., the program consisted of 12 rehabilitation exercise sessions (stretching, strengthening, chest and spine/hip joint flexibility exercises), which patients performed at home .
The limitations of our study include both selection bias of participants and study design. The study design was retrospective, based on data collection as part of clinical routine. Despite the clinical nature of this program and registration of variables which were standardised, data were missing in a high proportion of patients, particularly for some variables (e.g. BASDAI and BASFI). This emphasises that there is a need for more attention and focus, in clinical practice, to use recommended outcome measures in the follow-up and assessment of patients with inflammatory rheumatic disorders. In the updated 2010 ASAS/EULAR recommendations for the management of AS, disease monitoring of patients with AS is recommended to include data on e.g. patient history (e.g. questionnaires), clinical parameters and laboratory tests . Our experience demonstrates that disease monitoring in clinical practice is facilitated and has improved in our hospital after we started to use the GoTreatIT-rheuma® computer system (http://www.diagraphit.com), designed to monitor patients, in daily clinical practice, with inflammatory joint disorders . Furthermore, the ax-SpA patients we assessed were not a random selection of the ax-SpA population, followed in our out-patient clinic. Patients who did not have e.g. sufficient effect of medical treatment were more likely recruited. Another limitation, was the inclusion criteria which was only based on an overall judgement by the referral rheumatologist, that the patients were thought to benefit from this program. The lack of a control group also limits the scientific validity of the data, as the placebo effect was not controlled for and further includes both patient-reported outcome measures and therapist-measured outcomes. Another limitation of this study is that no intra-rater reliability tests were performed for the measurements used. However, for the metric measurement, BASMI, and for the patient reported outcome measures, BASDAI and BASFI, the instruments have been shown to be reliable, valid and sensitive to change [20, 32].
The strength of our study is that data have been captured from real life and based on how the ax-SpA patients have been handled in ordinary clinical practice. Thus, the design of this study enables us to test evidence-based treatment recommendations  and to validate if the effect of rehabilitation can also be demonstrated in clinical practice, after demonstration in clinical trials. Our data add evidence that organised and structured physiotherapy is of benefit for the ax-SpA patients. Probably, it has also been of advantage that all measures of physical function were performed by experienced physiotherapists, thus, reducing the risk of measurement errors.
Interestingly, our data indicate that the positive effect on BASMI, which is a composite physical measure of physical function, is also maintained after weeks and months after the training program is stopped. This positive findings should be interpreted with caution, as the follow-up measures of function for BASMI were not performed by the same assessor as during the 2-weeks training program.
Data from our retrospective case series report, support that patients with ax-SpA, benefit from short-term rehabilitation when carried out in ordinary clinical care. From a health service perspective “reality-based studies” are important when discussing the effectiveness of a treatment and allocating resources in the health care system.
- Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J: The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009, 68: 777-783. 10.1136/ard.2009.108233.PubMedView ArticleGoogle Scholar
- Van Der LS, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984, 27: 361-368. 10.1002/art.1780270401.View ArticleGoogle Scholar
- Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006, 65: 442-452. 10.1136/ard.2005.041137.PubMedPubMed CentralView ArticleGoogle Scholar
- Zochling J, Braun J: Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis. Expert Opin Pharmacother. 2006, 7: 869-883. 10.1517/146565220.127.116.119.PubMedView ArticleGoogle Scholar
- Toussirot E, Wendling D: Current guidelines for the drug treatment of ankylosing spondylitis. Drugs. 1998, 56: 225-240. 10.2165/00003495-199856020-00006.PubMedView ArticleGoogle Scholar
- Colina M, Ciancio G, Garavini R, Conti M, Trotta F, Govoni M: Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis. Int J Immunopathol Pharmacol. 2009, 22: 1125-1129.PubMedGoogle Scholar
- van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M: Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2001, 45: 430-438. 10.1002/1529-0131(200110)45:5<430::AID-ART362>3.0.CO;2-F.PubMedView ArticleGoogle Scholar
- Masiero S, Bonaldo L, Pigatto M, Lo Nigro A, Ramonda R, Punzi L: Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol. 2011, 38: 1335-1342. 10.3899/jrheum.100987.PubMedView ArticleGoogle Scholar
- Fernandez-de-Las-Penas C, Alonso-Blanco C, Morales-Cabezas M, Miangolarra-Page JC: Two exercise interventions for the management of patients with ankylosing spondylitis: a randomized controlled trial. Am J Phys Med Rehabil. 2005, 84: 407-419. 10.1097/01.phm.0000163862.89217.fe.PubMedView ArticleGoogle Scholar
- Ince G, Sarpel T, Durgun B, Erdogan S: Effects of a multimodal exercise program for people with ankylosing spondylitis. Phys Ther. 2006, 86: 924-935.PubMedGoogle Scholar
- Staalesen Strumse YA, Nordvag BY, Stanghelle JK, Roisland M, Winther A, Pajunen PA: Efficacy of rehabilitation for patients with ankylosing spondylitis: comparison of a four-week rehabilitation programme in a Mediterranean and a Norwegian setting. J Rehabil Med. 2011, 43: 534-542. 10.2340/16501977-0804.PubMedView ArticleGoogle Scholar
- Klokkerud M, Hagen KB, Lochting I, Uhlig T, Kjeken I, Grotle M: Does the content really matter? A study comparing structure, process, and outcome of team rehabilitation for patients with inflammatory arthritis in two different clinical settings. Scand J Rheumatol. 2012, 41: 20-28. 10.3109/03009742.2011.601757.PubMedView ArticleGoogle Scholar
- van den Berg R, Baraliakos X, Braun J, van der Heijde D: First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology. 2012, 51: 1388-1396. 10.1093/rheumatology/kes066.PubMedView ArticleGoogle Scholar
- Dagfinrud H, Kvien TK, Hagen KB: Physiotherapy interventions for ankylosing spondylitis. Cochrane database of systematic reviews (Online). 2008, 1: CD002822-Google Scholar
- Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011, 70: 896-904. 10.1136/ard.2011.151027.PubMedPubMed CentralView ArticleGoogle Scholar
- Curtis JR: Improving osteoporosis care through multimodal interventions: insights from the University of Alabama at Birmingham Center for Education and Research on Therapeutics. Osteoporos Int. 2011, 22 (Suppl 3): 445-450.PubMedPubMed CentralView ArticleGoogle Scholar
- Sung NS, Crowley WF, Genel M, Salber P, Sandy L, Sherwood LM: Central challenges facing the national clinical research enterprise. JAMA. 2003, 12: 1278-1287.View ArticleGoogle Scholar
- Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994, 21: 2286-2291.PubMedGoogle Scholar
- Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994, 21: 2281-2285.PubMedGoogle Scholar
- Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A: Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994, 21: 1694-1698.PubMedGoogle Scholar
- Csuka M, McCarty DJ: Simple method for measurement of lower extremity muscle strength. Am J Med. 1985, 78: 77-81.PubMedView ArticleGoogle Scholar
- Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM: American college of sports medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011, 43: 1334-1359. 10.1249/MSS.0b013e318213fefb.PubMedView ArticleGoogle Scholar
- van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M: Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005, 52: 1205-1215. 10.1002/art.20985.PubMedView ArticleGoogle Scholar
- van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005, 52: 582-591. 10.1002/art.20852.PubMedView ArticleGoogle Scholar
- Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004, 63: 1594-1600. 10.1136/ard.2004.020875.PubMedPubMed CentralView ArticleGoogle Scholar
- van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006, 54: 2136-2146. 10.1002/art.21913.PubMedView ArticleGoogle Scholar
- Mathieu S, Gossec L, Dougados M, Soubrier M: Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res. 2011, 63: 557-563. 10.1002/acr.20364.View ArticleGoogle Scholar
- Halvorsen S, Vollestad NK, Fongen C, Provan SA, Semb AG, Hagen KB: Physical fitness in patients with ankylosing spondylitis: comparison with population controls. Phys Ther. 2012, 92: 298-309. 10.2522/ptj.20110137.PubMedView ArticleGoogle Scholar
- Van Tubergen A, Boonen A, Landewe R, Rutten-Van Molken M, Van Der Heijde D, Hidding A: Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2002, 47: 459-467. 10.1002/art.10658.PubMedView ArticleGoogle Scholar
- Dagfinrud H, Halvorsen S, Vollestad NK, Niedermann K, Kvien TK, Hagen KB: Exercise programs in trials for patients with ankylosing spondylitis: do they really have the potential for effectiveness?. Arthritis Care Res. 2011, 63: 597-603.View ArticleGoogle Scholar
- Sokka T, Haugeberg G, Pincus T: Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUEST-RA global perspective. Clin Exp Rheumatol. 2007, 25 (6 Suppl 47): 86-97.PubMedGoogle Scholar
- Waldner A, Cronstedt H, Stenstrom CH: The Swedish version of the Bath ankylosing spondylitis disease activity index. Reliability and validity. Scand J Rheumatol Suppl. 1999, 111: 10-16.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.